Healthcare M&A and Valuation
News and Insights

On October 29, 2025, Thermo Fisher Scientific Inc. (NYSE: TMO)  announced a definitive agreement  to acquire Clario Holdings, Inc., a leading global provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg, Nordic Capital, Novo Holdings and Cinven for approximately $8.875 billion in cash at closing, with additional deferred and contingent payments of up to ~$525 million tied to future performance. The transaction, subject to customary re

In October 2025, ARCHIMED Diagnostics, the diagnostics-focused arm of global healthcare investment firm ARCHIMED, completed its acquisition of a 60% majority stake in ARK Diagnostics, Inc., a Fremont, California-based developer and manufacturer of specialty in vitro diagnostic (IVD) assays and tests, from South Korean specialty chemical company Soulbrain Holdings. The transaction values ARK at approximately $428 million enterprise value, with Soulbrain retaining a 40% minorit

On October 21, 2025, Hologic, Inc., a leading global medical technology company focused on women’s health diagnostics, imaging and surgical products, agreed to be acquired by funds managed by private equity firms Blackstone and TPG in a take‑private transaction valued at up to $18.3 billion in enterprise value. Under the definitive merger agreement, Hologic stockholders will receive $76 per share in cash plus a non‑tradable contingent value right (CVR) of up to $3 per share,

On October 2, 2025, New Enterprise Associates (NEA)  completed a take private transaction  involving NeueHealth, Inc., a provider of value-based care solutions that integrates patient engagement, care coordination, and provider enablement tools aimed at improving clinical outcomes and reducing total cost of care. NeueHealth’s platform partners with provider organizations and payors to deliver risk-bearing care models, leveraging data analytics, technology-driven workflows, an